Boehringer Bails On Biosimilars Outside US

 
• By Kevin Grogan

In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US while its version of Avastin has been abandoned altogether.

Statue of Liberty
US is land of opportunity for BI biosimilar • Source: Shutterstock

More from Biosimilars

More from Products